Maynard Um
-
-
-
-
-
-
-
Fate Therapeutics reports trial data on autoimmune treatments
-
-
-
-
-
-
-
Baird on Fate Therapeutics (FATE): 'Incrementally positive on FT819 enrollment ramp and early FT836 clinical data'
-
-
-
-
-
-
-
Fate Therapeutics (FATE) PT Lowered to $7 at Leerink Partners
-
-
-
-
-
-
-
Fate Therapeutics (FATE) names Matthew Abernethy to Board
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Reports In-Line Q4 EPS
-
-
-
-
-
-
-
TD Cowen Reiterates Hold Rating on Fate Therapeutics (FATE)
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Fate Therapeutics (FATE)
-
456,823 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

